Form 8-K - Current report:
SEC Accession No. 0000950170-22-006770
Filing Date
2022-05-02
Accepted
2022-05-02 07:06:25
Documents
16
Period of Report
2022-04-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K axsm-20220429.htm   iXBRL 8-K 58763
2 EX-99.1 axsm-ex99_1.htm EX-99.1 131077
3 EX-99.2 axsm-ex99_2.htm EX-99.2 23235
4 GRAPHIC img36028404_0.jpg GRAPHIC 55046
5 GRAPHIC img36951925_0.jpg GRAPHIC 55016
  Complete submission text file 0000950170-22-006770.txt   498128

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT axsm-20220429.xsd EX-101.SCH 2469
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT axsm-20220429_lab.xml EX-101.LAB 12798
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT axsm-20220429_pre.xml EX-101.PRE 9441
10 EXTRACTED XBRL INSTANCE DOCUMENT axsm-20220429_htm.xml XML 4540
Mailing Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007
Business Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37635 | Film No.: 22879357
SIC: 2834 Pharmaceutical Preparations